Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 30 (October 20), 2007: pp. 4722-4729
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.12.2440
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vredenburgh, J. J.
Right arrow Articles by Friedman, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vredenburgh, J. J.
Right arrow Articles by Friedman, H. S.
Related Articles
Right arrowRelated Editorial
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

James J. Vredenburgh, Annick Desjardins, James E. Herndon, II, Jennifer Marcello, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, John Sampson, Melissa Wagner, Leighann Bailey, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman

From the Preston Robert Tisch Brain Tumor Center; and the Departments of Surgery, Medicine, Biostatistics, Pediatrics, Neurobiology, and Pathology, Duke University Medical Center, Durham, NC

Address reprint requests to James J. Vredenburgh, MD, Duke University Medical Center, Box 3624, Durham, NC 27710; e-mail: vrede001{at}mc.duke.edu

Purpose The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan.

Patients and Methods This phase II trial included two cohorts of patients. The initial cohort, comprising 23 patients, received bevacizumab at 10 mg/kg plus irinotecan every 2 weeks. The dose of irinotecan was based on the patient's anticonvulsant: Patients taking enzyme-inducing antiepileptic drugs (EIAEDs) received 340 mg/m2, and patients not taking EIAEDs received 125 mg/m2. After this regimen was deemed safe and effective, the irinotecan schedule was changed to an accepted brain tumor regimen of four doses in 6 weeks, in anticipation of a phase III randomized trial of irinotecan versus irinotecan and bevacizumab. The second cohort, comprising 12 patients, received bevacizumab 15 mg/kg every 21 days and irinotecan on days 1, 8, 22, and 29. Each cycle was 6 weeks long and concluded with patient evaluations, including magnetic resonance imaging.

Results The 6-month progression-free survival among all 35 patients was 46% (95% CI, 32% to 66%). The 6-month overall survival was 77% (95% CI, 64% to 92%). Twenty of the 35 patients (57%; 95% CI, 39% to 74%) had at least a partial response. One patient developed a CNS hemorrhage, which occurred in his 10th cycle. Four patients developed thromboembolic complications (deep venous thrombosis and/or pulmonary emboli).

Conclusion Bevacizumab and irinotecan is an effective treatment for recurrent glioblastoma multiforme and has moderate toxicity.

Supported by Grants No. 5 P50 CA108786, 5 P50 NS20023, and 4 R37 CA11898 from the National Institutes of Health, Department of Health and Human Services, Bethesda, MD; the Preston Robert Tisch Brain Tumor Research Fund; and the Bryan Cless Research Fund. J.N.R. is a Damon Runyon-Lilly Clinical Investigator.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • Taming Glioblastoma: Targeting Angiogenesis
    Eric T. Wong and Steven Brem
    JCO 2007 25: 4705-4706 [Full Text]

Related Correspondence

  • Bevacizumab Plus Irinotecan in Recurrent Glioblastoma
    Marc C. Chamberlain
    JCO 2008 26: 1012-1013 [Full Text]
  • Fewer Dollars, More Sense
    David H. Garfield and Aleck Hercbergs
    JCO 2008 26: 5304-5305 [Full Text]


This article has been cited by other articles:


Home page
 Neuro OncologyHome page
H. Colman, L. Zhang, E. P. Sulman, J. M. McDonald, N. L. Shooshtari, A. Rivera, S. Popoff, C. L. Nutt, D. N. Louis, J. G. Cairncross, et al.
A multigene predictor of outcome in glioblastoma
Neuro Oncology, October 20, 2009; (2009) nop007v1.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
F. M. Iwamoto, L. E. Abrey, K. Beal, P. H. Gutin, M. K. Rosenblum, V. E. Reuter, L. M. DeAngelis, and A. B. Lassman
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
Neurology, October 13, 2009; 73(15): 1200 - 1206.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. S. Friedman, M. D. Prados, P. Y. Wen, T. Mikkelsen, D. Schiff, L. E. Abrey, W.K. A. Yung, N. Paleologos, M. K. Nicholas, R. Jensen, et al.
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
J. Clin. Oncol., October 1, 2009; 27(28): 4733 - 4740.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Razis, P. Selviaridis, S. Labropoulos, J. L. Norris, M.-J. Zhu, D. D. Song, T. Kalebic, M. Torrens, A. Kalogera-Fountzila, G. Karkavelas, et al.
Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment
Clin. Cancer Res., October 1, 2009; 15(19): 6258 - 6266.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Medical OncologyHome page
J. S.W. Lind and E. F. Smit
Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancer
Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 95 - 107.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
A. K. Lucio-Eterovic, Y. Piao, and J. F. de Groot
Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy
Clin. Cancer Res., July 15, 2009; 15(14): 4589 - 4599.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
W. B. Pope, H. J. Kim, J. Huo, J. Alger, M. S. Brown, D. Gjertson, V. Sai, J. R. Young, L. Tekchandani, T. Cloughesy, et al.
Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment
Radiology, July 1, 2009; 252(1): 182 - 189.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. G. Sorensen, T. T. Batchelor, W.-T. Zhang, P.-J. Chen, P. Yeo, M. Wang, D. Jennings, P. Y. Wen, J. Lahdenranta, M. Ancukiewicz, et al.
A "Vascular Normalization Index" as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
Cancer Res., July 1, 2009; 69(13): 5296 - 5300.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
G. Karpel-Massler, U. Schmidt, A. Unterberg, and M.-E. Halatsch
Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?
Mol. Cancer Res., July 1, 2009; 7(7): 1000 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. van den Bent, M. A. Vogelbaum, P. Y. Wen, D. R. Macdonald, and S. M. Chang
End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
J. Clin. Oncol., June 20, 2009; 27(18): 2905 - 2908.
[Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. S. Shord, L. R. Bressler, L. A. Tierney, S. Cuellar, and A. George
Understanding and managing the possible adverse effects associated with bevacizumab
Am. J. Health Syst. Pharm., June 1, 2009; 66(11): 999 - 1013.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. S. Chi, A. G. Sorensen, R. K. Jain, and T. T. Batchelor
Angiogenesis as a Therapeutic Target in Malignant Gliomas
Oncologist, June 1, 2009; 14(6): 621 - 636.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Taillibert, L. A. Vincent, B. Granger, Y. Marie, C. Carpentier, R. Guillevin, A. Bellanger, K. Mokhtari, A. Rousseau, D. Psimaras, et al.
Bevacizumab and irinotecan for recurrent oligodendroglial tumors
Neurology, May 5, 2009; 72(18): 1601 - 1606.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Chamberlain
Cilengitide: Does It Really Represent a New Targeted Therapy for Recurrent Glioblastoma?
J. Clin. Oncol., April 10, 2009; 27(11): 1921 - 1921.
[Full Text] [PDF]

Home page
 NeurologyHome page
P. L. Nghiemphu, W. Liu, Y. Lee, T. Than, C. Graham, A. Lai, R. M. Green, W. B. Pope, L. M. Liau, P. S. Mischel, et al.
Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience
Neurology, April 7, 2009; 72(14): 1217 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
J.N. Rich and C.E. Eyler
Cancer Stem Cells in Brain Tumor Biology
Cold Spring Harb Symp Quant Biol, March 27, 2009; (2009) sqb.2008.73.060v1.
[Abstract] [PDF]

Home page
 JCOHome page
T. N. Kreisl, L. Kim, K. Moore, P. Duic, C. Royce, I. Stroud, N. Garren, M. Mackey, J. A. Butman, K. Camphausen, et al.
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
J. Clin. Oncol., February 10, 2009; 27(5): 740 - 745.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
J. J. Vredenburgh, A. Desjardins, D. A. Reardon, and H. S. Friedman
Experience with irinotecan for the treatment of malignant glioma
Neuro-oncol, January 1, 2009; 11(1): 80 - 91.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
E. C. Quant, A. D. Norden, J. Drappatz, A. Muzikansky, L. Doherty, D. LaFrankie, A. Ciampa, S. Kesari, and P. Y. Wen
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Neuro-oncol, January 1, 2009; 11(5): 550 - 555.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
S. M. Chang, J. Clarke, and P. Wen
Novel Imaging Response Assessment for Drug Therapies in Recurrent Malignant Glioma
ASCO Educational Book, January 1, 2009; 2009(1): 107 - 111.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
P. Y. Wen, A. D. Norden, and J. Drappatz
Antiangiogenic Therapies for Malignant Gliomas
ASCO Educational Book, January 1, 2009; 2009(1): 113 - 117.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. J. Svensson, J. E. Welch, P. Kucharzewska, P. Bengtson, M. Bjurberg, S. Pahlman, G. B. Ten Dam, L. Persson, and M. Belting
Hypoxia-Mediated Induction of the Polyamine System Provides Opportunities for Tumor Growth Inhibition by Combined Targeting of Vascular Endothelial Growth Factor and Ornithine Decarboxylase
Cancer Res., November 15, 2008; 68(22): 9291 - 9301.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. H. Garfield and A. Hercbergs
Fewer Dollars, More Sense
J. Clin. Oncol., November 10, 2008; 26(32): 5304 - 5305.
[Full Text] [PDF]

Home page
 JCOHome page
J. J. Vredenburgh, J. N. Rich, D. A. Reardon, A. Desjardins, and H. S. Friedman
In Reply:
J. Clin. Oncol., November 10, 2008; 26(32): 5305 - 5305.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Desjardins, D. A. Reardon, J. E. Herndon II, J. Marcello, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson, L. Bailey, et al.
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Clin. Cancer Res., November 1, 2008; 14(21): 7068 - 7073.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
E. S. Paulson and K. M. Schmainda
Comparison of Dynamic Susceptibility-weighted Contrast-enhanced MR Methods: Recommendations for Measuring Relative Cerebral Blood Volume in Brain Tumors
Radiology, November 1, 2008; 249(2): 601 - 613.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
N. G. Gottardo and A. Gajjar
Chemotherapy for Malignant Brain Tumors of Childhood
J Child Neurol, October 1, 2008; 23(10): 1149 - 1159.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
L. W Buie and J. Valgus
Bevacizumab: A Treatment Option for Recurrent Glioblastoma Multiforme
Ann. Pharmacother., October 1, 2008; 42(10): 1486 - 1490.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Idbaih, F. Ducray, M. Sierra Del Rio, K. Hoang-Xuan, and J.-Y. Delattre
Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors
Oncologist, September 1, 2008; 13(9): 978 - 992.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
S. M. Chang, K. R. Lamborn, J. G. Kuhn, W.K. A. Yung, M. R. Gilbert, P. Y. Wen, H. A. Fine, M. P. Mehta, L. M. DeAngelis, F. S. Lieberman, et al.
Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium
Neuro-oncol, August 1, 2008; 10(4): 631 - 642.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. Y. Wen and S. Kesari
Malignant Gliomas in Adults
N. Engl. J. Med., July 31, 2008; 359(5): 492 - 507.
[Full Text] [PDF]

Home page
 JCOHome page
M. C. Chamberlain
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma
J. Clin. Oncol., February 20, 2008; 26(6): 1012 - 1013.
[Full Text] [PDF]

Home page
 JCOHome page
S. Sathornsumetee, Y. Cao, J. E. Marcello, J. E. Herndon II, R. E. McLendon, A. Desjardins, H. S. Friedman, M. W. Dewhirst, J. J. Vredenburgh, and J. N. Rich
Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan
J. Clin. Oncol., January 10, 2008; 26(2): 271 - 278.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
S. Kesari, D. Schiff, J. W. Henson, A. Muzikansky, D. C. Gigas, L. Doherty, T. T. Batchelor, J. A. Longtine, K. L. Ligon, S. Weaver, et al.
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults
Neuro-oncol, January 1, 2008; 10(3): 300 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
P. Nghiemphu, R. M. Green, W. B. Pope, A. Lai, and T. F. Cloughesy
Safety of anticoagulation use and bevacizumab in patients with glioma
Neuro-oncol, January 1, 2008; 10(3): 355 - 360.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. T. Wong and S. Brem
Taming Glioblastoma: Targeting Angiogenesis
J. Clin. Oncol., October 20, 2007; 25(30): 4705 - 4706.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online